Bilateral refractory pneumothorax treated by pleurodesis and bronchial occlusion in a COVID-19 patient

Satoshi Tanaka; Yoshihiro Takayama; Riiko Kitou; Ryo Asakawa; Satoshi Tobita; Akihiro Ike; Masahiro Kawada; Suguru Yamamoto; Kiyonobu Ueno

doi:10.1002/ccr3.6754

Bilateral refractory pneumothorax treated by pleurodesis and bronchial occlusion in a COVID-19 patient

Clin Case Rep. 2022 Dec 21;10(12):e6754. doi: 10.1002/ccr3.6754. eCollection 2022 Dec.

Authors

Satoshi Tanaka¹, Yoshihiro Takayama¹, Riiko Kitou¹, Ryo Asakawa¹, Satoshi Tobita¹, Akihiro Ike², Masahiro Kawada³, Suguru Yamamoto¹, Kiyonobu Ueno¹

Affiliations

¹ Department of Respiratory Medicine Osaka General Medical Center Osaka Japan.
² Department of Thoracic Surgery Osaka General Medical Center Osaka Japan.
³ Division of Trauma and Surgical Critical Care Osaka General Medical Center Osaka Japan.

Abstract

Coronavirus disease 2019 (COVID-19) has become a worldwide outbreak, and it can cause various symptoms and complications. However, pneumothorax secondary to COVID-19 is relatively uncommon. We herein report a 60-year-old man with bilateral refractory pneumothorax with severe COVID-19. In patients with poor general health and who are difficult to undergo surgery for pneumothorax post-COVID-19, internal treatments such as chest drainage, bronchial occlusion, and pleurodesis are essential to relieving refractory pneumothorax. It also indicates that autologous blood patch pleurodesis is a useful method in terms of efficacy and side effects.

Keywords: COVID‐19; bilateral pneumothorax; bronchial occlusion; chest drainage; pleurodesis.

Publication types

Case Reports